Physician profile
Daniel C Hood
NPI 1639127970
$4,911.03
in general payments reported to CMS, 2019-2025
34 companies · $827 in 2025
The $827 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $130 · 2021: $428 · 2022: $648 · 2023: $643 · 2024: $1,022 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,491.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $642.54 | 2019-2024 | Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $563.00 | 2022-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $476.64 | 2019-2025 | |
| Emd Serono, INC. | $415.20 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $354.13 | 2019-2024 | Vumerity, Tysabri |
| Medtronic USA, INC. | $340.83 | 2019 | |
| Eisai INC. | $331.11 | 2024-2025 | |
| Insightec,INC | $181.78 | 2021-2023 | Exablate |
| Lilly USA, LLC | $122.20 | 2019 | |
| Celgene Corporation | $119.23 | 2022-2024 | Zeposia |
| Jazz Pharmaceuticals INC. | $107.42 | 2023 | |
| Acadia Pharmaceuticals INC | $106.74 | 2024-2025 | Nuplazid |
| Pfizer INC. | $105.74 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $99.43 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $90.80 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $87.97 | 2019-2024 | Amplatzer Talisman |
| Ucb, INC. | $86.40 | 2024-2025 | Nayzilam, Briviact, Fintepla |
| Genentech USA, INC. | $84.83 | 2021-2025 | Ocrevus Zunovo |
| Vanda Pharmaceuticals INC. | $56.06 | 2024-2025 | Ponvory |
| Argenx US, INC. | $52.97 | 2022-2024 | Vyvgart Hytrulo |
| Neurelis, INC. | $51.42 | 2023-2025 | Valtoco |
| Genzyme Corporation | $46.52 | 2019 | |
| Tg Therapeutics, INC. | $44.81 | 2024-2025 | |
| Greenwich Biosciences, INC. | $42.49 | 2020 | |
| Supernus Pharmaceuticals, INC. | $39.80 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $37.04 | 2023 | Ingrezza, Ongentys |
| Genentech, INC. | $35.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.07 | 2024-2025 | Hyqvia |
| Janssen Pharmaceuticals, INC | $30.87 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $29.81 | 2022 | |
| Lundbeck LLC | $29.41 | 2023 | Vyepti |
| Sk Life Science, INC. | $28.32 | 2024 | |
| Acorda Therapeutics, INC | $21.14 | 2019 | |
| Csl Behring | $17.49 | 2025 | Hizentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.